ELE. E. Larionova

E. E. Larionova

*This is an algorithmically generated author record based on publicly available information.

E. E. Larionova has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The first experience of using bedaquiline in the treatment of pulmonary mycobacteriosis in children with cystic fibrosis

    by L. V. Panova, E. S. Ovsyankina, E. I. Kondratyeva, I. Yu. Petrakova, T. G. Smirnova, E. E. Larionova, L. E. Kharakhashyan, M. V. Erzutova

    Patients with cystic fibrosis (CF) have the highest risk of developing pulmonary mycobacteriosis. A pressing issue is the introduction of new drugs, such as bedaquiline, into pediatric clinical practice, as these drugs have shown proven efficacy against nontuberculous mycobacteria (NTM) in microbiological studies. The aim of this study was to demonstrate the first experience of using bedaquiline in the treatment of pulmonary mycobacteriosis in two 14-year-old boys with CF. Conclusion. Clinical, laboratory, and radiographic tests demonstrated the efficacy of bedaquiline when included in mycobacteriosis treatment regimens. A good tolerability was noted. Persistent isolation of Mycobacterium abscessus after 12 months of treatment in case 1 and M. intracellulare after 6 months in case 2 were considered carrier states. The use of bedaquiline did not result in the expected eradication of NTM, confirming the need for continued research and the search for new drugs for the treatment of pulmonary mycobacteriosis in patients with CF and implementation of these drugs into clinical practice.


  • Frequency of Resistance to Delamanid in Mycobacterium tuberculosis Isolated from Patients with Pulmonary Tuberculosis in the Russian Federation

    by S. N. Andreevskaya, T. G. Smirnova, E. E. Larionova, E. A. Kiseleva, Yu. V. Maslennikova, L. N. Chernousova, A. E. Ergeshov

    Delamanid is one of the key new drugs for the treatment of multidrug-resistant and, in particular, extensively drug-resistant tuberculosis. However, due to its relatively recent introduction into clinical practice, data on the frequencу of resistance detection to this drug remain limited. The aim of the study was to determine the phenotypic susceptibility of Mycobacterium tuberculosis , isolated from patients with pulmonary tuberculosis in the Russian Federation, to delamanid. Materials and methods. The study included a total of 271 M. tuberculosis isolates with different resistance pat terns, obtained from patients in the Russian Federation (2022–2025). Resistance to delamanid (pure substance, Otsuka Pharmaceutical Co., Ltd., Japan) was determined using a modified proportional assay in the BACTEC MGIT 960 system; the critical concentration for delamanid was 0.06 µg/mL. Results . Resistance to delamanid was detected in 14.39% (39/271) of cases in both M. tuberculosis isolates susceptible to other anti-tuberculosis drugs and M. tuberculosis isolates with resistance profiles including 1 to 10 drugs (excluding delamanid). The incidence of delamanid resistance in M. tuberculosis with retained susceptibility to rifampin and in M. tuberculosis with multidrug/extensive drug resistance did not differ significantly, amounting to 11.49% and 15.76%, respectively. Primary resistance to delamanid was detected in at least 3.69% (10/271) of the cases. Conclusion. The data obtained indicate a significant level of resistance to delamanid, including among isolates not exposed to the drug. Therefore, it is imperative to improve measures to control the spread of pathogens resistant to this antimicrobial agent.

  • Open Access

    Osobennosti genotipicheskoj rezistentnosti k ftorhinolonam u Mycobacterium tuberculosis, cirkuliruyushchih v Rossijskoj Federacii

    by С. Н. Андреевская, Т. Г. Смирнова, Л. Н. Черноусова, Е. Е. Ларионова, Е. А. Киселева, А. Эргешов

  • The nature of genotypic resistance to fluoroquinolones in Mycobacterium tuberculosis circulating in Russian Federation

    by Sn Andreevskaya, Tg Smirnova, Ln Chernousova, Ee Larionova, Ea Kiseleva, A Ergeshov

    Fluoroquinolones are the main group of drugs used for treatment of multidrug resistant tuberculosis (MDR-TB). The study was aimed to assess the diversity of mutation in the gyrA gene and to evaluate the association of gyrA mutations with the phenotypic resistance to levofloxacin and the general drug resistance profile of the pathogen. The study involved assessment of diagnostic materials obtained from 2836 patients with pulmonary tuberculosis. TB-BIOCHIP-2 and AmplitubeFQ-RV kits were used for identification of the gyrA mutations. Phenotypic drug susceptibility of M. tuberculosis (MTB) was defined using the BACTEC MGIT 960 test system. It was shown that mutations D94G (41.63%; 95% CI: 38.03–45.32%) and A90V (21.32%; 95% CI: 18.44–24.50%) prevailed in MBT, although some isolates carrying these mutations were obtained from the newly diagnosed patients with pulmonary tuberculosis. It was found that mutation D94A was not strongly associated with the phenotypic resistance to fluoroquinolones. Fluoroquinolone resistance was usually associated with multiple drug resistance (93.52%; 95% CI 91.43–95.12%). In 2.31% (95% CI 1.78–3.00%) of cases, genotypic heteroresistance to fluoroquinolones was detected: mixed populations included 2–4 MTB pools with various structure of the gyrA QRDR. The results obtained lead to the conclusion that resistance to fluoroquinolones that is usually associated with the existing MDR arises in the modern MTB population. MTB carrying gyrA mutations D94G and A90V seems to be the most promising in evolutionary terms.


  • Open Access

    Problems of anti-tuberculosis therapy in patients on hemodialysis

    by O. M. Gordeeva, A. M. Tikhonov, S. N. Andreevskaya, E. E. Larionova, N. L. Karpina

    Цель исследования: определить возможность назначения и безопасность применения различных противотуберкулезных препаратов и их комбинаций в рамках терапевтического или профилактического курса противотуберкулезной терапии (ПТТ) у больных в терминальной стадии хронической болезни почек (ТХБП), получающих заместительную терапию гемодиализом в условиях высокой распространенности штаммов микобактерий туберкулеза (МБТ) с лекарственной устойчивостью. Материалы и методы. Под наблюдением в ФГБНУ «ЦНИИТ» находилось 42 больных, получающих заместительную терапию гемодиализом: с активным туберкулезом – 31 (73,8%) чел., с остаточными посттуберкулезными изменениями органов дыхания – 11 (26,2%) чел. За период наблюдения проведена оценка характера и степени тяжести нежелательных реакций на противотуберкулезные препараты. Результаты. У больных ТХБП с туберкулезом органов дыхания преобладают лекарственно-устойчивые штаммы возбудителя – 68,2%. Среди нежелательных явлений при приеме противотуберкулезных препаратов встречались: нарастание явлений уремии ‒ в 20,5% наблюдений, сердечно-сосудистые осложнения – в 17,9% и нейротоксические реакции – в 15,4%. Нарастание уремии при приеме противотуберкулезных препаратов у наблюдаемых больных встречалось достоверно чаще, чем гепатотоксические реакции (p = 0,02). При лечении туберкулеза у больных ТХБП из-за нежелательных явлений требовалась отмена изониазида в 12,8% наблюдений и пиразинамида в 12,8% наблюдений, другие препараты реже. Индивидуализированный подбор ПТТ с учетом данных теста лекарственной чувствительности МБТ, противопоказаний, сопутствующих заболеваний позволил подобрать адекватную ПТТ больным ТХБП с туберкулезной инфекцией в 92,9% на срок более 6 мес.

  • Open Access

    Evaluation of Predictors of the Effectiveness of Bronchoscopic Biopsies with Navigation by Endobronchial Ultrasound Mini Probes in Peripheral Lung Masses of Various Etiologies

    by I. Yu. Shabalina, Ya. O. Chesalina, E. E. Larionova, Yu. S. Berezovskiy, O. V. Lovacheva, А. E. Ergeshov, Ю. С. Березовский

    The objective of the study: to evaluate and compare the predictors of effectiveness of navigation bronchobiopsy – radial endobronchial ultrasound with mini probes (rEBUS) in patients with peripheral pulmonary tumors of tuberculosis and oncological origin.Subjects and Methods. The effectiveness of rEBUS-guided bronchoscopic biopsies and predictors of this effectiveness were retrospectively analyzed in 152 patients (71 men and 81 women) with pulmonary tumors visualized by chest computed tomography (CT) as peripheral lung masses. All patients were divided into 2 groups according to the verified diagnoses: TB Group included 83 patients with pulmonary tuberculosis without bacterial excretion at the time of bronchological examination; NEO Group included 69 patients with pulmonary neoplasms.In all patients of both groups, a bronchological examination was performed for diagnostic purposes and included several types of biopsies (a set of biopsies): at least one of the liquid biopsies (bronchoalveolar lavage (BAL) or bronchial lavage) and one tissue biopsy (transbronchial lung biopsy (TBLB) or brush biopsy). Specimens of all types of bronchobiopsy were sent for microbiological and cytological tests, and the TBLB samples were additionally sent for histological examination.Results. The efficiency of diagnosing bronchobiopsy with rEBUS navigation in TB and NEO Groups was comparable – 81.9% (68/83) and 81.2% (56/69) (pχ2 > 0.05), respectively. The factors (predictors) that statistically significantly influenced on effectiveness of bronchobiopsy in both groups were the following: signs of draining bronchus on chest CT, visualization of the mass in general during rEBUS, central position of the ultrasound probe in the mass during navigation, localization of the mass in the upper lobe of the right lung versus the lower lobe (summarized in two groups).Additionally for TB Group, the predictor was the size of the mass exceeding 20 mm.The effectiveness of cytological and histological verification in NEO Group with brush biopsy and TBLB samples significantly surpassed the effectiveness in TB Group, but the microbiological diagnosis of M. tuberculosis in BAL/bronchial lavage specimens increased the effectiveness in TB Group and made it comparable to NEO Group.


  • Open Access

    Bronchoscopic biopsies with radial endobronchial ultrasonographic navigation in the diagnosis of tuberculosis and mycobacteriosis in patients with peripheral lung masses

    by I. Yu. Shabalina, A. S. Zaytseva, A. I. Popova, E. E. Larionova, O. V. Lovacheva, A. E. Ergeshov

    The objective of the study: to evaluate the effectiveness of diagnosis of tuberculosis and mycobacteriosis in bronchobiopsy specimens obtained during navigation by radial endobronchial ultrasonography (rEBUS) in patients with peripheral lung lesions without bacterial excretion.Subjects and methods. A retrospective analysis of the diagnostic effectiveness of bronchoscopic examination with biopsies was carried out in 179 patients (75 men and 104 women) suffering from pulmonary tuberculosis or mycobacteriosis without bacterial excretion; peripheral lung lesions had been visualized by computed tomography (CT). The patients were divided into two groups: 93 underwent bronchoscopy with biopsies with rEBUS navigation, 86 underwent bronchoscopy with classical biopsies and preliminary CT navigation. Each patient underwent multiple biopsies, at least one fluid biopsy (bronchoalveolar lavage or bronchial lavage), and one tissue biopsy (transbronchial lung biopsy or brush biopsy). Specimens collected by all types of bronchobiopsy were sent for microbiological and cytological tests, specimens of pulmonary transbronchial biopsy were additionally sent for histological examination.Results. The diagnosis of tuberculosis was verified by bronchobiopsy in 106 (67.5%) of 158 patients with tuberculosis, but statistically significantly more often in the group with rEBUS navigation versus the group without it – 81.9% (68/83) versus 50.7% (38/75), respectively (pχ2 < 0.01). The diagnosis of non-tuberculous mycobacteriosis was verified by bronchobiopsy in 13 (61.9%) of 21 patients, in the group with rEBUS navigation – in 80.0% (8/10) patients, in the group without it – in 45.5% (5/11) (pφ > 0.05). The use of rEBUS navigation while collecting bronchobiopsy specimens made it possible to increase the etiological verification of tuberculosis using the following microbiological methods: microscopy – from 14.7 to 49.4% (pχ2 < 0.01), molecular genetic – from 41.3 to 72.3% ( pχ2 < 0.01), culture (Bactec MGIT960) – from 44.0 to 67.5% (pχ2 < 0.01) The greatest enhancement of diagnostic effectiveness was achieved in the specimens of bronchoalveolar lavage and bronchial lavage – from 33.3 to 71.1% (pχ2 < 0.01) and in brush biopsy specimens – from 25.6 to 57.6% (pχ2 < 0.01).


  • Open Access

    DETECTION OF NON-TUBERCULOUS MYCOBACTERIA IN MARI EL REPUBLIC

    by Yoshkar-Ola Republican Tb Dispensary, L. V. Petrova, Е. И. Мельникова, Yu. A. Soloviev, E. E. Larionova, E. V. Sevastyanova, Ю. А. Соловьев

    ВЫЯВЛЕНИЕ НЕТУБЕРКУЛЕЗНЫХ МИКОБАКТЕРИЙ В РЕСПУБЛИКЕ МАРИЙ ЭЛ


  • Open Access

    First Draft Genome Sequence of a Mycobacterium gordonae Clinical Isolate

    by V. Ustinova, T. Smirnova, K. Blagodatskikh, D. Varlamov, D. Sochivko, E. Larionova, S. Andreevskaya, I. Andrievskaya, L. Chernousova

    Here, we report the first draft genome sequence of the clinically relevant species Mycobacterium gordonae. The clinical isolate Mycobacterium gordonae 14-8773 was obtained from the sputum of a patient with mycobacteriosis.